[Personalized medicine in non-small-cell carcinoma]

Fukuoka Igaku Zasshi. 2014 Mar;105(3):57-66.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / genetics
  • Cell Cycle Proteins / genetics*
  • Cisplatin / administration & dosage
  • ErbB Receptors / genetics*
  • Gene Fusion / genetics*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Microtubule-Associated Proteins / genetics*
  • Molecular Targeted Therapy*
  • Mutation
  • Precision Medicine* / trends
  • Protein-Tyrosine Kinases / genetics
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins c-ret / genetics
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Serine Endopeptidases / genetics*

Substances

  • Cell Cycle Proteins
  • Microtubule-Associated Proteins
  • Proto-Oncogene Proteins
  • Carboplatin
  • Anaplastic Lymphoma Kinase
  • EGFR protein, human
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-ret
  • RET protein, human
  • ROS1 protein, human
  • Receptor Protein-Tyrosine Kinases
  • EML4 protein, human
  • Serine Endopeptidases
  • Cisplatin